Applied Clinical Trials-04-01-2020

Industry experts weigh in on how much traditional approaches in clinical operations need to change to meet new expectations for clinical delivery.

Lockstep with regulatory guidance on conducting trials amid crisis, here are four key actions sponsors can take to minimize disruptions.

Click the title above to open the Applied Clinical Trials April 2020 issue in an interactive PDF format.

COVID-19 will not only leave a long legacy on public health, but it may also force companies that have been lagging behind the disruption curve to adopt technologies and processes that will make clinical trials more efficient.

That question will likely hinge on EFPIA's ability to uphold its commitment to "work with governments and health systems to ensure that when new treatments and vaccines are approved, they are available and affordable.”

Expert in rare disease patient registries discusses ways to address hurdles in setting up observational cohort clinical studies.

A compilation of recent notable news developments that pertain to the clinical trials industry.

Outlining the three concerns communicated the most when it comes to implementing an FSP outsourcing strategy.

Examining the advantages of a program-wide data strategy in advancing high-efficiency drug development.

New agency initiatives aim is to fully reflect the impact of treatment on patients representing a range of ages, ethnic backgrounds, and other demographic features